A Reference Formulation for the Calibration of Barrier-Coherent Systems

Version 1.1 · Hydra Chronic Analytical Series

Abstract

This document defines a theoretical reference formulation for the calibration of the Hydra Chronic Barrier Integrity Framework (BIF).

It is not proposed as a product, a clinical recommendation, or a commercially viable specification. It is a structured analytical construct: a reasoned formulation architecture designed to examine whether the requirements represented by the four BIF dimensions can be assembled within a single internally coherent system under conditions of compromised skin barrier physiology.

Each component decision is justified by reference to primary literature on skin barrier physiology, lipid organization, and formulation–barrier interaction.

The objective is not optimization and not demonstration of clinical efficacy. It is the establishment of a defined analytical reference against which formulation architecture, evidentiary requirements, and departures from a minimal barrier-coherent system can be examined.

The reference is theoretical. Where product-specific empirical information would be required for a BIF determination, theoretical compatibility is not treated as equivalent to demonstrated fulfilment.

1. Scope and Status of This Document

This document does not constitute:

- a therapeutic or cosmetic recommendation
- a commercially viable product specification
- a claim of clinical efficacy
- a safety assessment
- a regulatory assessment
- evidence of performance in vivo

It is:

- an analytical construct designed to examine the internal consistency of a formulation under defined physiological constraints
- a reference architecture for application of the Barrier Integrity Framework
- a means of identifying the information required to distinguish structural plausibility from an assessable formulation
- a theoretical demonstration of how the requirements represented by the four BIF dimensions may be addressed within one formulation architecture

The formulation described here has not been manufactured, tested in vivo, or submitted for regulatory review.

Its function is methodological, not practical.

Accordingly, this document distinguishes throughout between theoretical structural compatibility and a formal BIF determination based on sufficient evidence.

2. Theoretical Basis

The reference formulation is derived from three constraints corresponding to physiological demands relevant to compromised skin barrier systems.

2.1 Structural Constraint

Barrier-compromised skin is associated with alterations in stratum corneum organization, including disruption of intercellular lipid architecture.

Ceramides, cholesterol, and free fatty acids contribute to the organization and function of the extracellular lipid matrix. Alteration of this system is associated with impaired barrier function in several compromised skin states.

A barrier-coherent formulation should therefore avoid introducing unnecessary structural stress and should employ a formulation architecture compatible with the physiological organization of the stratum corneum.

The reference does not assume that the presence of individual barrier-associated lipids establishes barrier reconstruction. Ingredient presence and structural coherence are analytically distinct.

2.2 Physiological Constraint

Compromised skin may exhibit altered pH homeostasis, increased permeability, reduced tolerance thresholds, and increased susceptibility to inflammatory or irritative stress.

An acidic stratum corneum environment contributes to processes involved in barrier homeostasis, including enzyme activity and lipid processing.

The reference system is therefore constructed around compatibility with the functional pH corridor defined by the applicable BIF operational criteria.

Compatibility cannot be inferred solely from the absence of obviously alkaline ingredients. A formal pH Coherence determination requires the evidence specified in the applicable BIF Analysis Protocol.

2.3 Variability Constraint

Skin barrier states are not static.

Interindividual variation, disease activity, environmental exposure, anatomical site, and other physiological variables can influence barrier function and response to topical formulations.

The reference therefore does not represent a universal physiological optimum. It is constructed for the defined analytical context of compromised barrier conditions.

Its purpose is to minimize avoidable structural conflict within that context rather than to predict equivalent behaviour across all individuals or pathological states.

3. Formulation Architecture

The reference formulation follows a minimal-coherent architecture.

In this document, minimal-coherent describes a system in which each component class has an explicit formulation or physiological function and in which unnecessary structural complexity is deliberately restricted.

It does not mean that minimal ingredient count is itself a criterion of coherence.

The architecture is organized around five principles:

Lipid-oriented architecture

The lipid phase is designed to provide emollience and surface continuity without implying reconstruction of the complete stratum corneum lipid system.

Restricted emulsifier burden

The emulsification system is selected and constrained to minimize unnecessary interfacial stress while maintaining formulation integrity.

Avoidance of unnecessary barrier-disruptive mechanisms

The reference does not deliberately employ strong surfactant systems, aggressive penetration enhancement, fragrance materials, or other components whose principal function would conflict with the purpose of the model.

Controlled humectant system

Hydration support is incorporated without assuming that increasing humectant concentration necessarily improves coherence under compromised barrier conditions.

Restricted active complexity

The reference is not designed to demonstrate therapeutic activity. High active complexity is therefore excluded unless required for the structural logic of the model.

These principles translate the theoretical constraints defined in Section 2 into a formulation architecture. They are design conditions, not substitutes for empirical evidence.

4. Component Architecture and Rationale

The following components constitute the theoretical reference architecture.

Component	Function	Analytical rationale
Caprylic/Capric Triglyceride	Emollient; lipid phase	Provides a relatively simple emollient component within the lipid architecture
Squalane	Emollient; film formation	Stable hydrocarbon emollient compatible with a lipid-oriented surface system
Shea Butter	Emollient; lipid provision	Contributes a complex lipid fraction while remaining secondary to the structural logic of the system
Hydrogenated Lecithin	Emulsification; structural organization	Selected for its phospholipid character and potential compatibility with lamellar or pseudo-lamellar formulation architecture

Glycerin	Primary humectant	Provides hydration support within a controlled humectant system
Pentylene Glycol	Secondary humectant; formulation support	Included only under concentration conditions compatible with the defined tolerance constraints
Ceramide NP	Barrier-associated lipid component	Provides a defined barrier-related lipid element without implying complete physiological lipid replacement
Hydroxyethylcellulose	Rheology; stabilization	Provides formulation structure without an intended active barrier function
Xanthan Gum	Rheology; stabilization	Supports physical formulation stability
Carbomer	Viscosity control	Provides rheological control where compatible with the defined final physicochemical conditions

The presence of these components does not by itself establish BIF fulfilment.

Concentration, material specification, final formulation architecture, physicochemical conditions, and relevant interactions remain part of the assessment.

4.1 Lipid Phase

Caprylic/Capric Triglyceride, Squalane, and Shea Butter constitute the primary lipid-phase architecture of the reference system.

Their inclusion is intended to establish an emollient and surface-oriented lipid environment without claiming replication of the extracellular lipid matrix of the stratum corneum.

Squalane provides a stable hydrocarbon emollient. Shea Butter introduces a more complex lipid fraction, including unsaponifiable components. Caprylic/Capric Triglyceride provides a comparatively simple emollient component.

The analytical rationale concerns their function within the formulation system. Their presence should not be interpreted as evidence that the final formulation necessarily improves barrier function.

4.2 Emulsification System

Hydrogenated Lecithin is selected as the principal emulsification component because its phospholipid character makes it a plausible candidate for a formulation architecture intended to avoid unnecessary membrane or lamellar disruption.

Lecithin-based systems may form organized structures depending on composition and processing conditions.

This potential is not equivalent to demonstration that the final reference system forms a lamellar structure. A formal Barrier Architecture determination would require evidence concerning the actual formulation architecture where the applicable operational criterion depends on that property.

The emulsifier concentration must likewise be defined before concentration-dependent compatibility can be formally assessed.

4.3 Humectant System

Glycerin is retained as the primary humectant because of its established relevance to stratum corneum hydration and barrier recovery.

Pentylene Glycol is retained as a secondary formulation component with humectant and preservation-support functions.

Its inclusion is explicitly concentration-dependent.

The reference therefore does not assume that Pentylene Glycol is compatible at any concentration. The combined humectant and glycol burden must remain within the conditions established by the applicable operational criteria and supporting evidence.

4.4 Barrier-Associated Lipid Component

Ceramide NP is included as a defined barrier-associated lipid component.

The reference deliberately does not claim that Ceramide NP alone reconstructs the stratum corneum lipid matrix.

Physiological barrier lipid organization involves relationships among ceramides, cholesterol, free fatty acids, and other structural variables. A complete reconstruction claim would therefore require substantially more specific compositional and structural evidence.

Ceramide NP is retained here because it permits the model to examine the role of a barrier-associated lipid within the wider formulation architecture without treating ingredient presence as proof of barrier repair.

4.5 Rheology and Stability System

Hydroxyethylcellulose, Xanthan Gum, and Carbomer are included for rheological control and physical stabilization.

They are not assigned a barrier-restorative function.

Their relevance to the BIF lies principally in whether their concentrations, interactions, processing requirements, and effects on final formulation conditions introduce conflicts elsewhere in the system.

Their inclusion therefore remains subject to the same evidence requirements as other formulation components.

5. Deliberate Exclusions

Exclusion is treated as a design decision within the reference architecture.

The following categories are not deliberately incorporated:

- high-load surfactant systems
- fragrance materials and essential oils
- aggressive penetration-enhancing systems
- unnecessary high-dose active systems
- formulation components whose inclusion cannot be justified within the defined purpose of the reference

The original reference architecture also excluded PEG-based emulsification systems. This should not be interpreted as a general BIF rule that PEG-containing formulations are inherently incoherent.

Under the current Framework, compatibility is assessed according to the specific component, concentration, formulation context, exposure conditions, and available evidence.

No ingredient class fails BIF assessment merely by category name unless an applicable operational criterion and sufficient evidence establish an exclusion condition.

The exclusion architecture of this reference is therefore intentionally conservative. It reduces variables that are unnecessary to the purpose of the model.

It does not constitute a general safety or efficacy judgment regarding excluded components.

6. Defined Reference Conditions

For the reference architecture to function as an assessable calibration system, architectural plausibility must be distinguished from product-specific evidence.

The following variables require explicit specification before a formal four-dimensional BIF determination can be made:

- quantitative component concentrations or defined concentration ranges
- material specifications where composition affects the relevant criterion
- final formulation pH
- evidence relevant to maintenance of the defined pH condition where required by the applicable operational criterion
- emulsification and manufacturing parameters where these determine formulation architecture
- evidence of lamellar or other claimed structural organization where such organization forms part of the determination
- relevant physicochemical properties
- concentration-dependent compatibility information
- delivery conditions where a delivery claim or mechanism is analytically relevant

These requirements are deliberate.

A theoretical formulation should not receive a more permissive evidentiary standard than a formulation assessed under the BIF.

The reference therefore serves not only as a structural model but also as a demonstration of analytical accessibility requirements.

7. Evaluation Against the BIF Dimensions

The reference architecture can be examined against each BIF dimension.

However, the status values Fulfilled, Not Fulfilled, and Not Assessable are governed by the current BIF Analysis Protocol.

Theoretical plausibility alone does not establish Fulfilled.

7.1 Barrier Architecture

The lipid-oriented architecture, restricted emulsification system, controlled humectant system, and barrier-associated lipid component provide a structurally plausible basis for Barrier Architecture.

However, ingredient selection alone does not demonstrate the organization of the final formulation.

Where fulfilment depends on properties such as actual lamellar organization, quantitative lipid relationships, or other empirically verifiable formulation characteristics, those properties require the evidence specified by the operational criteria.

Reference assessment: Structurally compatible by design; formal status dependent on completion of the required evidence set.

7.2 pH Coherence

The reference system is intended to operate within the functional pH corridor specified by the applicable BIF operational criteria.

This is a design requirement of the reference formulation.

The absence of soap-based emulsifiers or obviously alkaline components is insufficient to demonstrate that the final formulation operates within that corridor.

Final formulation pH must therefore be specified or measured according to the applicable protocol, together with any additional evidence required for a positive pH Coherence determination.

pH Coherence is a non-compensable dimension. Where it is Not Assessable, and no independent Not Fulfilled finding determines the outcome, an overall coherence verdict cannot be issued.

Reference assessment: Required by design; formal fulfilment requires the specified pH evidence.

7.3 Membrane Compatibility

The reference architecture deliberately avoids several classes of components whose primary function would increase membrane or barrier perturbation.

This provides a conservative starting architecture.

It does not establish membrane compatibility by absence alone.

Compatibility remains dependent on component identity, concentration, formulation context, relevant interactions, and the evidentiary requirements defined by the applicable operational criteria.

Membrane Compatibility is a non-compensable dimension.

Reference assessment: No deliberate membrane-disruptive mechanism is introduced; formal fulfilment remains evidence-dependent.

7.4 Delivery Logic

The reference does not seek deep active delivery.

Its intended action is predominantly surface-oriented, and no aggressive penetration-enhancing or encapsulation strategy is incorporated.

Ceramide NP is treated as a formulation component within the structural architecture rather than as evidence of targeted delivery.

The resulting delivery concept is therefore deliberately limited: the system does not claim to overcome the compromised barrier in order to transport an active to a deeper biological target.

Where no additional active-delivery claim is made, the Delivery Logic assessment concerns whether the formulation architecture and intended site of action are internally consistent.

Reference assessment: Delivery concept is internally limited by design; formal status remains subject to the applicable operational criteria and available evidence.

8. Relationship Between Reference Architecture and BIF Verdict

The reference formulation is not automatically classified as Coherent because it was constructed as a reference.

It is subject to the same analytical rules as any formulation examined under the Barrier Integrity Framework.

This is methodologically essential.

If sufficient evidence supports all four dimensions, the applicable verdict may be issued in accordance with the BIF Analysis Protocol.

If evidence is insufficient for a dimension, that dimension is classified as Not Assessable.

If a defined exclusion criterion is demonstrated, the relevant dimension is Not Fulfilled.

The reference therefore calibrates the Framework not by presupposing a positive outcome, but by providing a deliberately constrained system against which the Framework's evidence requirements and decision rules can be applied.

9. Limitations of the Reference System

The following limitations are explicit and intentional:

- The formulation does not represent an optimal treatment or optimal barrier reconstruction.
- It does not establish clinical efficacy.
- It does not reproduce the complete lipid complexity of the stratum corneum.
- It does not address every pathological skin state.
- It does not predict individual tolerability.
- It has not been manufactured or tested in vivo.
- No clinical validation has been conducted.
- The existing reference architecture does not contain a complete quantitative formulation specification.
- It therefore cannot, in its present theoretical form, generate positive empirical findings for criteria that require product-specific measurement or quantitative evidence.

These limitations are not exceptions to the BIF methodology.

They are an application of it.

Where information is absent, the Framework preserves that uncertainty rather than converting structural plausibility into demonstrated coherence.

10. Function of the Reference

The reference serves three principal analytical functions within the Barrier Integrity Framework.

Reference architecture

It provides a deliberately constrained formulation system against which the structural logic of more complex formulations can be examined.

It is not a mandatory template. Deviation from the reference does not constitute failure.

Analytical stress test

Additional components, formulation mechanisms, or structural claims can be introduced conceptually and examined for the new evidentiary requirements or potential inconsistencies they create.

The purpose is not to reward simplicity but to make additional complexity analytically visible.

Framework calibration

The reference tests whether the BIF can distinguish among:

- structural plausibility
- sufficient evidence
- insufficient evidence
- demonstrated inconsistency

A useful calibration system must be capable of producing Not Assessable where its own evidence is insufficient.

The reference therefore does not validate the Framework by producing a predetermined positive verdict. It tests whether the Framework applies its rules consistently even to a formulation designed around its own constraints.

11. Concluding Statement

This reference formulation is not an answer to compromised skin.

It is a constraint model.

Its purpose is not to demonstrate efficacy and not to define a universally preferred formulation.

It establishes a controlled analytical architecture within which the relationships among formulation composition, physiological constraints, evidentiary sufficiency, and structural coherence can be examined.

A formulation may depart substantially from this reference and still demonstrate structural coherence under the BIF.

Such departure is not itself a negative finding.

What matters is whether the alternative architecture can be assessed against the same defined criteria and whether the evidence supports the resulting determination.

The reference therefore establishes a point of analytical comparison, not a formulation standard.

Selected References

The following references informed the physiological reasoning of the original reference formulation. This list is indicative and does not constitute an independent revalidation of the cited propositions in this revision.

Akihisa, T. et al. Anti-inflammatory and chemopreventive effects of triterpene cinnamates and acetates from shea fat. Journal of Oleo Science.

Ananthapadmanabhan, K.P. et al. Cleansing without compromise: the impact of cleansers on the skin barrier and the technology of mild cleansing. Dermatologic Therapy.

Bouwstra, J.A. et al. Structure of the skin barrier and its modulation by vesicular formulations. Progress in Lipid Research.

Elias, P.M. Structure and function of the stratum corneum extracellular matrix. Journal of Investigative Dermatology.

Fluhr, J.W. and Darlenski, R. Skin barrier function. Karger.

Fluhr, J.W. et al. Glycerol accelerates recovery of barrier function in vivo. Acta Dermato-Venereologica.

Hachem, J.P. et al. Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome. Journal of Investigative Dermatology.

Loden, M. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders. American Journal of Clinical Dermatology.

Noh, M. and Lee, C.H. Skin microbiome and its interplay with the environment. Journal of Dermatological Science.

Proksch, E. et al. The skin: an indispensable barrier. Experimental Dermatology.

SCCS (Scientific Committee on Consumer Safety). Notes of Guidance for the Testing of Cosmetic Substances and Their Safety Evaluation. European Commission.

Surber, C. and Maibach, H.I. Topical Drug Bioavailability, Bioequivalence, and Penetration. Springer.

Document Status

Document Status	In Force
Version	1.1
Scope	BIF Reference Architecture
Issued by	Hydra Chronic, Berlin
Document Series	Hydra Chronic Analytical Series
Supersedes	Reference Formulation v1.0